Rate Video

GU Cancers 2019 | Nrf2 inhibitors to overcome chemoresistance

Simon Crabb • 15 Feb 2019

GU Cancers 2019

Bladder Cancer Genitourinary Cancer Cisplatin

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, talks about targeting Nrf2 signaling pathways to overcome resistance to chemotherapeutic agents in bladder cancer. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Not enough attention paid to bone health in prostate cancer

Key prostate cancer news from GU 2019

Simon Crabb • 15 Feb 2019

SPIRE trial: overcoming cisplatin resistance in bladder cancer with transcriptome changes

Simon Crabb • 15 Feb 2019

Beyond cancer treatment: nurse specialists in the clinic

Related Videos

PSMA dRT: PSMA PET/CT before radiotherapy in prostate cancer

Jeremie Calais • 22 Apr 2021

Clinical utility of liquid biopsies in prostate cancer

Arpit Rao • 19 Apr 2021

Upcoming advances in prostate cancer: PARPi, CDK4/6, lutetium PSMA therapy & CAR-T approaches

Arpit Rao • 19 Apr 2021

RAMP: Phase Ib study of rucaparib & enzalutamide in mCRPC

Arpit Rao • 19 Apr 2021